Suboxone Tapering Guide
buprenorphine / naloxone
Boxed Warning
Risk of life-threatening respiratory depression and death with concurrent benzodiazepines or other CNS depressants. Risk of dependence and abuse.
Overview
Buprenorphine/naloxone is a partial opioid agonist combination used for opioid use disorder treatment. Buprenorphine partial agonism produces a "ceiling effect" reducing overdose risk; naloxone is added to deter injection (it precipitates withdrawal if injected, but is not absorbed sublingually).
2/0.5mg, 4/1mg, 8/2mg, 12/3mg sublingual films/tablets
Sublingual film: 2/0.5, 4/1, 8/2, 12/3mg; Sublingual tablet: 2/0.5, 8/2mg; Subcutaneous depot (Sublocade): monthly buprenorphine alone
Category C
Mechanism of Action
Buprenorphine: partial agonist at mu opioid receptors with high binding affinity, kappa antagonist. Naloxone: opioid antagonist (active only if injected).
Taper Notes
Very slow taper. Compounded liquid or microdosing strategies are often required at the low end. Plan with an addiction-medicine specialist.
Hyperbolic Tapering Guidance
Buprenorphine taper is one of the longer ones in psychiatry. Hyperbolic reductions, especially below 2mg, are usually necessary. Many patients choose long-term maintenance over taper given relapse risk.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
24-72 hours after last dose (slower than short-acting opioids)
3-7 days
Acute symptoms 2-4 weeks
Post-acute withdrawal (anhedonia, sleep, anxiety) can last 3-12 months
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- CNS depressants (benzodiazepines, alcohol) — additive respiratory depression risk
- Strong CYP3A4 inhibitors/inducers — alter exposure
- Other opioids — variable interactions
Contraindications
- Known hypersensitivity
- Severe hepatic impairment (relative)
Toxicity
Respiratory depression (less than full agonists due to ceiling), sedation, constipation, dizziness, sweating, dental problems with sublingual use. Precipitated withdrawal if started while another full agonist is on board.
Pharmacokinetics
ADME Profile
Hepatic via CYP3A4 (buprenorphine).
~96% (buprenorphine)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Suboxone (buprenorphine / naloxone) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- SAMHSA — Medication-Assisted Treatment — Federal guidance on MAT for opioid use disorder
- Deprescribing.org — opioid algorithm — Evidence-based opioid deprescribing algorithm
- CDC Clinical Practice Guideline for Prescribing Opioids — 2022 CDC guideline on opioid prescribing for chronic pain
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- SAMHSA National Helpline — 24/7 confidential support for substance use and mental health
- Mad in America — opioid coverage — Independent journalism on opioid tapering and recovery
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for medication withdrawal
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.